The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Current approaches and new approvals in MF and PV
Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, discusses the current therapeutic options available to patients with myeloproliferative neoplasms (MPNs). Young patients with myelofibrosis (MF) will receive allogeneic hematopoietic stem-cell transplantation as first line, if eligible, which is the only potentially curative therapy available. Ruxolitinib and fedratinib are used when transplantation is not an option. For patients with polycythemia vera (PV), ropeginterferon alfa-2b, has recently been approved for use regardless of treatment history. Prof. Barbui talks on the promise of this novel agent, as well as new investigational therapies in clinical trials. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
